ClinicalTrials.gg
RecruitingNCT07010263AK112-311Updated Mar 5, 2026

A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

A Phase 3 interventional study of AK112 and Placebo in Small Cell Lung Cancer, sponsored by Akeso. Recruiting at 53 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
560
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Planned enrollment
24th of 333
560 · median 63
Started
2025
with 59 others
Phase 3
57 of 365
23 open now
Primary completion
2028-12
later than 177 of 214 live
Registered
287th of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 24th largest by planned enrollment of the 333 interventional ones that give a count, is one of 60 that started in 2025, is one of 57 in phase 3, reaches primary completion later than 177 of the 214 other live ones, and was the 287th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK112 to placebo as consolidation treatment for patients with limited stage small cell lung cancer who have not progressed following concurrent chemoradiation therapy.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • AK112
  • Ivonescimab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria:

  1. The subjects voluntarily participated in the study with full and signed written informed consent form.
  2. Aged ≥18 years on day fo signing the informed consent.
  3. (ECOG) performance status of 0 or 1.
  4. ≥ 3 months
  5. or cytologically confirmed small cell lung cancer.
  6. Documented limited-stage SCLC (Stage I-III SCLC [T any, N any, M0] according to the American Joint Committee on Cancer Staging Manual [AJCC Cancer Staging Manual, 8th Edition] or the Veterans Administration Lung Study Group (VALG) stage.
  7. Have Received concurrent chemoradiotherapy regimen as defined in protocol and have not progressed following concurrent chemoradiotherapy.
  8. Adequate organ function.
  9. Women of must have a negative serum pregnancy test within 7 days prior to the first dose and agree to take effective measures during the study drug administration and within 120 days after the last dose.

Exclusion Criteria:

  1. Histologically or cytological confirmed the presence of mixed small cell lung cancer or non-small cell lung cancer components.
  2. Toxicities from previous anti-tumor treatments have not resolved to grade 0 or 1 based on the National Cancer Institute (NCI CTCAE v5.0), or to the levels specified in inclusion/exclusion criteria, except for alopecia.
  3. Symptoms or signs of primary disease deterioration that the investigator judges clinically unacceptable, such as cachexia.
  4. Presence of pleural effusion, pericardial effusion, or ascites, which was clinically symptomatic or requiring frequent drainage.
  5. History of active malignant tumors within the previous 5 years.
  6. Received major surgery within 28 days prior to the first dose of study drug, or expected to undergo major surgery during the study period within 28 days after the first dose of study drug.
  7. Uncontrolled comorbidities, including but not limited to decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, and other related diseases..
  8. Have serious neurological or mental illnesses, including dementia and epileptic seizures.
  9. Pregnant or lactating women.
  10. Have cardiovascular or cerebrovascular diseases or risk factors.
  11. Prior treatments with systemic non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc.) within 2 weeks before the first administration of the study drugs. Prior treatment with Chinese herbal medicine or traditional Chinese patent medicines with anti-tumor indications within 1 weeks before the first administration of the study drugs.
  12. Prior treatments targeting immune mechanisms, including, but not limited to, , immune checkpoint agonists, immune cell therapy.
  13. Prior treatments with anti-angiogenic therapy.
  14. Subjects requiring systemic treatment with (>10mg/day prednisone or equivalent dose) or other drugs within 14 days prior to the first dose of study drug.
  15. Known history of severe reactions to other monoclonal antibodies or with a known history of allergy or hypersensitivity reactions to any of study drugs or their components.
  16. Active diseases that require systemic treatment within 2 years prior to the study, or autoimmune diseases that the investigator judges to be potentially recurrent or require planned treatment.
  17. Known interstitial lung disease or non infectious pneumonia, which currently has symptoms or requires systemic corticosteroid treatment in the past,or investigator juges may affect the toxicity assessment or management related to the study treatment.
  18. Known severe infection within 4 weeks prior to the first dose of study drug. Known active tuberculosis. Known active syphilis infection. Known history of immunodeficiency or positive test results.
  19. .Known history of allogeneic organ transplantation and hematopoietic stem cell transplantation.
  20. Active or active .
  21. Received a within 30 days prior to the first dose of study drug, or planning to receive a live vaccine during the study period.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
560 participants (estimated)

Study arms

  • Experimental
    Ak112 arm

    AK112 intravenous \[IV\]),every 3 weeks

    Drug: AK112

  • Placebo comparator
    Placebo arm

    Placebo intravenous \[IV\]),every 3 weeks

    Other: Placebo

Interventions

  • DrugAK112

    AK112 20mg/kg, intravenous \[IV\]),Q3W

    Also known as: Ivonescimab

  • OtherPlacebo

    Placebo, intravenous \[IV\]),Q3W

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival(PFS) assessed by Blinded independent center review(BIRC)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST v1.1

    Time frame: Approximately 6 years

  2. Overall Survival (OS)

    OS is defined as the time from randomization or first dosing to death due to any cause.

    Time frame: Approximately 6 years

Secondary outcomes

  1. PFS assessed by investigator per RECIST v1.1

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST v1.1

    Time frame: Approximately 6 years

  2. Objective Response Rate (ORR) assessed by BICR Per RECIST v1.1

    Time frame: Approximately 6 years

  3. ORR assessed by investigator Per RECIST v1.1

    Time frame: Approximately 6 years

  4. Disease control rate(DCR) assessed by BICR per RECIST v1.1

    Time frame: Approximately 6 years

  5. DCR assessed by investigator per RECIST v1.1

    Time frame: Approximately 6 years

  6. Duration of Response (DOR) assessed by BICR per RECIST v1.1

    Time frame: Approximately 6 years

  7. DOR assessed by investigator per RECIST v1.1

    Time frame: Approximately 6 years

  8. Number of participants with adverse event (AE)

    The number of participants experiencing an AE and the severity of AEs will be assessed. AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF, whether or not considered related to the study treatment.

    Time frame: Approximately 6 years

07

Study locations

52 of 53 sites recruiting
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Rong Yu, M.D. · Contact
    • Rong Yu, M.D. · Principal investigator
  • The First Medical Center of Chinese PLA General Hospital
    Beijing, Beijing Municipality 100853, China
    Recruiting
    • Yi Hu, M.D. · Contact
    • Yi Hu, M.D. · Principal investigator
  • Beijing Chest Hospital
    Beijing, Beijing Municipality 101149, China
    Recruiting
    • Gen Lin, M.D. · Contact
    • Gen Lin, M.D. · Principal investigator
  • Beijing Luhe Hospital, Capital Medical University
    Beijing, Beijing Municipality 101149, China
    Recruiting
    • Dong Yan, M.D. · Contact
    • Dong Yan, M.D. · Principal investigator
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijin, Beijin 100021, China
    Recruiting
    • Zhijie Wang, M.D. · Contact
    • Zhijie Wang, M.D. · Principal investigator
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400016, China
    Recruiting
    • Ge Luo, M.D. · Contact
    • Ge Luo, M.D. · Principal investigator
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Recruiting
    • Haipeng Xu, M.D. · Contact
    • Haipeng Xu, M.D. · Principal investigator
  • PLA No. 900 Hospital of the Joint Support Force
    Fuzhou, Fujian 350025, China
    Recruiting
    • Zongyang Yu, M.D. · Contact
    • Zongyang Yu, M.D. · Principal investigator
  • Longyan First Hospital
    Longyan, Fujian 364000, China
    Recruiting
    • Chunyue Wang, M.D. · Contact
    • Chunyue Wang, M.D. · Principal investigator
  • Zhangzhou Municipal Hospital of Fujian Province
    Zhangzhou, Fujian 363000, China
    Recruiting
    • Li Lin, M.D. · Contact
    • Li Lin, M.D. · Principal investigator
  • Gansu Provincial Cancer Hospital
    Lanzhou, Gansu 730050, China
    Recruiting
    • Shihong Wei, M.D. · Contact
    • Shihong Wei, M.D. · Principal investigator
  • Jiangmen Central Hospital
    Jiangmen, Guangdong 529030, China
    Recruiting
    • Gengsheng Yu, M.D. · Contact
    • Gengsheng Yu, M.D. · Principal investigator
  • Liuzhou People's Hospital
    Liuzhou, Guangxi 545006, China
    Recruiting
    • Leili Wang, M.D. · Contact
    • Leili Wang, M.D. · Principal investigator
  • Affiliated Cancer Hospital of Guangxi Medical University
    Nanning, Guangxi 530021, China
    Recruiting
    • Jiangqiong Huang, M.D. · Contact
    • Jiangqiong Huang, M.D. · Principal investigator
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530021, China
    Recruiting
    • Qing Bu, M.D. · Contact
    • Qing Bu, M.D. · Principal investigator
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangzhou 510080, China
    Recruiting
    • Jing Li, M.D. · Contact
    • Jing Li, M.D. · Principal investigator
  • Guizhou Provincial People's Hospital
    Guiyang, Guizhou 400042, China
    Recruiting
    • Yu Zhang, M.D. · Contact
    • Yu Zhang, M.D. · Principal investigator
  • The Second Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou 563000, China
    Recruiting
    • Shiyun Xing, M.D. · Contact
    • Shiyun Xing, M.D. · Principal investigator
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050011, China
    Recruiting
    • Jun Wang, M.D. · Contact
    • Jun Wang, M.D. · Principal investigator
  • Tangshan People's Hospital
    Tangshan, Hebei 063001, China
    Recruiting
    • Zhiwu Wang, M.D. · Contact
    • Zhiwu Wang, M.D. · Principal investigator
    • Guilan Dong, M.D. · Principal investigator
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
    Recruiting
    • Yan Yu, M.D. · Contact
    • Yan Yu, M.D. · Principal investigator
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150086, China
    Recruiting
    • Yu Yang, M.D. · Contact
    • Yu Yang, M.D. · Principal investigator
  • Anyang Cancer Hospital
    Anyang, Henan 455000, China
    Recruiting
    • Anping Zheng, M.D. · Contact
    • Anping Zheng, M.D. · Principal investigator
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan 453100, China
    Recruiting
    • Qingqin Zhang, M.D. · Contact
    • Qingqin Zhang, M.D. · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
    Recruiting
    • Yanqiu Zhao, M.D. · Contact
    • Yanqiu Zhao, M.D. · Principal investigator
  • Jingzhou First People's Hospital
    Jingzhou, Hubei 434000, China
    Recruiting
    • Yonghua Yang, M.D. · Contact
    • Yonghua Yang, M.D. · Principal investigator
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    Not yet recruiting
    • Xiaorong Dong, M.D. · Contact
    • Xiaorong Dong, M.D. · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
    Recruiting
    • Yongzhong Luo, M.D. · Contact
    • Yongzhong Luo, M.D. · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
    Recruiting
    • Lin Wu, M.D. · Contact
    • Lin Wu, M.D. · Principal investigator
    • Huai Liu, M.D. · Principal investigator
  • The First Affiliated Hospital of South China University
    Hengyang, Hunan 421001, China
    Recruiting
    • Yuehua Li, M.D. · Contact
    • Yuehua Li, M.D. · Principal investigator
  • General Hospital of the PLA Eastern Theater Command
    Nanjing, Jiangsu 210002, China
    Recruiting
    • Xiangfeng Lv, M.D. · Contact
    • Xiangfeng Lv, M.D. · Principal investigator
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210009, China
    Recruiting
    • Lin Shi, M.D. · Contact
    • Lin Shi, M.D. · Principal investigator
  • Xuzhou Municipal Hospital
    Xuzhou, Jiangsu 221002, China
    Recruiting
    • Haitao Yin, M.D. · Contact
    • Haitao Yin, M.D. · Principal investigator
  • The First Affiliated Hospital of Gannan Medical University
    Gannan, Jiangxi 341000, China
    Recruiting
    • Jie Li, M.D. · Contact
    • Jie Li, M.D. · Principal investigator
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Longhua Sun, M.D. · Contact
    • Longhua Sun, M.D. · Principal investigator
  • Jilin Cancer Hospital
    Changchun, Jilin 130000, China
    Recruiting
    • Haifeng Liu, M.D. · Contact
    • Haifeng Liu, M.D. · Principal investigator
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
    Recruiting
    • Bo Jin, M.D. · Contact
    • Bo Jin, M.D. · Principal investigator
  • Ningxia Medical University General Hospital
    Yinchuan, Ningxia 750004, China
    Recruiting
    • Yanyang Wang, M.D. · Contact
    • Yanyang Wang, M.D. · Principal investigator
  • Shandong Provincial Hospital
    Jinan, Shandong 250021, China
    Recruiting
    • Zhe Yang, M.D. · Contact
    • Zhe Yang, M.D. · Principal investigator
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    Recruiting
    • Hui Zhu, M.D. · Contact
    • Hui Zhu, M.D. · Principal investigator
  • Linyi Cancer Hospital
    Linyi, Shandong 276000, China
    Recruiting
    • Jianhua Shi, M.D. · Contact
    • Jianhua Shi, M.D. · Principal investigator
  • Linyi People's Hospital
    Linyi, Shandong 276000, China
    Recruiting
    • Zhongmin Zhang, M.D. · Contact
    • Xueliang Xu, M.D. · Sub investigator
    • Zhongmin Zhang, M.D. · Principal investigator
  • Qingdao Central Hospital of Health and Rehabilitation Sciences University
    Qingdao, Shandong 266000, China
    Recruiting
    • Zhen Zhang, M.D. · Contact
    • Xiaotao Zhang, M.D. · Contact
    • Zhen Zhang, M.D. · Principal investigator
    • Xiaotao Zhang, M.D. · Principal investigator
  • Zaozhuang Municipal Hospital
    Zaozhuang, Shandong 277100, China
    Recruiting
    • Shifeng Kan, M.D. · Contact
    • Shifeng Kan, M.D. · Principal investigator
  • Weifang No.2 People's Hospital
    Weifang, Shangdong 261041, China
    Recruiting
    • Kunning Yang, M.D. · Contact
    • Kunning Yang, M.D. · Principal investigator
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Zhengfei Zhu, M.D. · Contact
    • Zhengfei Zhu, M.D. · Principal investigator
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 200433, China
    Recruiting
    • Fengying Wu, M.D. · Contact
    • Fengying Wu, M.D. · Principal investigator
  • Shanxi Cancer Hospital
    Taiyuan, Shanxi 300013, China
    Recruiting
    • Hongwei Li, M.D. · Contact
    • Hongwei Li, M.D. · Principal investigator
  • Tangdu Hospital, The Fourth Military Medical University
    Xi’an, Shanxi 710038, China
    Recruiting
    • Xiaolong Yan, M.D. · Contact
    • Xiaolong Yan, M.D. · Principal investigator
  • Mianyang Central Hospital
    Mianyang, Sichuan 621000, China
    Recruiting
    • Xiaobo Du, M.D. · Contact
    • Xiaobo Du, M.D. · Principal investigator
  • Tianjin Cancer Hospital
    Tianjin, Tianjin Municipality 300060, China
    Recruiting
    • Dingzhi Huang, M.D. · Contact
    • Dingzhi Huang, M.D. · Principal investigator
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Shaxi, Xi'an 710061, China
    Recruiting
    • Yu Yao, M.D. · Contact
    • Yu Yao, M.D. · Principal investigator
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
    Recruiting
    • Yuping Li, M.D. · Contact
    • Yuping Li, M.D. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2028, 42 months after the start.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 42 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2025
First posted
Jun 8, 2025
StartActual
Jun 13, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jul 31, 2029
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07010263
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jun 8, 2025
Start date
Jun 13, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Mar 5, 2026

Study contacts

Zhifang Yao, M.D.
Contact
clinicaltrials@akesobio.com
+86-0760-89873999

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion